Avita Medical, Inc. Common Stock RCEL
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $11.40 (+1.8% upside)
Key Stats
- Today's Range
- $10.80 – $11.39
- 50-Day Range
- $3.78 – $11.39
- 52-Week Range
- $3.22 – $11.39
- Volume
- 302K shs
- Average Volume
- 590K shs
- Market Cap
- $346.38 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -12.44
- Price / Sales
- 4.58
Short Interest
- Short Interest
- 0.34%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $75.63 million
- Net Income
- $-43,082,000
- Net Margin
- -56.96%
- Return on Equity
- 154.76%
- Debt-to-Equity
- —
About Avita Medical, Inc. Common Stock
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Related Stocks
Compare head-to-head: RCEL vs SYK·RCEL vs BSX·RCEL vs RMD·RCEL vs BAX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.